GW Pharmaceuticals' Preliminary Q4 Revenue of $108 Million Beats Expectations

GW Pharmaceuticals (NASDAQ: GWPH) released its preliminary fourth-quarter results for 2019 on Sunday. Sales for the quarter totaled $108 million, with $104 million of that coming from the company's popular cannabidiol (CBD)-based drug, Epidiolex.